Tibbitts Gregory J 4

What Happened

• Gregory J. Tibbitts, a director of Mainz Biomed N.V. (MYNZ), received a grant of 45,000 restricted shares on February 13, 2026. The shares were reported at $0.00 per share (no cash consideration was paid).
• This transaction is an award/grant (compensation), not an open-market purchase or sale, so it reflects company compensation rather than a direct buy or sell signal.

Key Details

• Transaction date: 2026-02-13; reported on Form 4 filed 2026-02-19.
• Transaction type/code: A — Award/Grant of restricted shares.
• Price: $0.00 per share (no cash paid upon grant).
• Shares transferred: 45,000 restricted shares granted.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: F1 — Grant made under Mainz Biomed N.V. 2025 Omnibus Incentive Plan; no cash consideration. F2 — Separately, 10,875 employee stock options were granted and previously reported on a Form 3 filed Jan 26, 2026.
• Filing timeliness: The Form 4 was filed six days after the reported transaction (filed 2026-02-19 for a 2026-02-13 transaction), which is after the typical two-business-day window for Form 4 filings and may be considered late.

Context

• Restricted share awards are usually subject to vesting and are compensation rather than an indication the insider is buying or selling based on current market views. The filing does not show any immediate sale of these shares or tax-withholding transactions.
• The separate note about employee stock options (F2) refers to an earlier reported grant on a Form 3 and is not the subject of this Form 4 entry.